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95 ANALYSIS OF SYNOVIAL FLUID BIOMARKERS IN PATIENTS
WITH RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, AND
NORMAL DONORS
R. Kokebie1, A. Yanke1, A.A. Hakimiyan1, M. Michalska1, D.C. Rueger2,
J.A. Block1, S. Chubinskaya1. 1Rush University Medical Center,
Chicago, IL, USA, 2Stryker Biotech, Hopkinton, MA, USA
Purpose: To compare synovial ﬂuid (SF) biomarker levels in samples
from patients with rheumatoid (RA), osteoarthritis (OA), and normal organ
donors for prognostic/diagnostic purposes.
Methods: Synovial ﬂuid (SF) was collected from the knees of 45 (6 males
and 39 females) OA, 22 (14 females and 8 males) RA patients and 20
(15 females and 5 males) normal organ donors. Eight biomarkers ana-
lyzed by ELISA methods were evaluated: interleukin (IL)-1, Il-6, Il-8, Il-11,
leukemia inﬂammatory factor (LIF), cartilage oligomeric protein (COMP),
osteocalcin, and osteogenic protein-1 (OP-1). Multivariate analysis as-
sessed the effects of gender and disease activity: WOMAC scores for OA
samples, and SF WBC, ESR, CRP for RA samples. Multivariant Kruskal-
Wallis and Mann-Whitney Tests were used; p< 0.05 was considered
signiﬁcant.
Results: The mean (±SD) age was: 53±9 years for OA, 54±11 for RA,
and 52±7 for donors. No gender differences were identiﬁed between
markers. In RA SF, the levels of 4 out of 5 tested cytokines/chemokines
were higher than in OA and normal SF. The most signiﬁcant differences
were found for Il-6 and Il-8, where Il-6 concentration was 2.5-fold higher
than in OA, 2587.59±6393.69 vs. 1045.68±5451.13 øg/ml, respectively
(p< 0.005), and 8-fold higher than in normal, 2587.59±6393.69 vs.
339.06±906.28, respectively (P< 0.002). The levels of Il-8 were 8-fold
higher than in OA, 6490.04±16550.74 vs 849.48 øg/ml, respectively
(P< 0.0005) and normal, 6490.04±16550.74 vs 788.69±837.705 øg/ml,
respectively (P< 0.028). The differences for Il-11 were not as substantial,
especially between RA and OA samples, while it was a 5-fold differ-
ence between OA and normal SF, 654.11±1411.844 øg/ml, respectively
(P< 0.003). The value of Il-1 was signiﬁcantly higher in normal than OA,
9.81±2.72 vs 8.56±7.06 øg/ml, respectively (P< 0.004); in the RA, it was
a tendency for a higher concentration of Il-1 than in OA and normal, but it
did not reach signiﬁcance. Surprisingly, concentration of LIF was higher in
normal samples than in RA (P< 0.044) and OA (P< 0.001). The highest
levels of OP-1 were found in normal SF (541.92±28.61 ng/ml), which
were almost 5-fold higher than in OA (112.40±124.64) (P< 0.001) and
more than 2-fold higher than in RA SF (202.25±149.13 ng/ml, P< 0.001).
No differences were detected in the levels of COMP or osteocalcin
between the experimental groups. Although the differences between
active and inactive states of OA or RA were insigniﬁcant, for cytokines and
OP-1 each state was statistically different from normal. SF from both OA
and RA had higher biomarker levels than normals, regardless of disease
state, though there was a trend of higher chemokine levels in less active
RA, and higher Il-1, Il-6, and Il-8 levels in active OA.
Conclusions: Our ﬁndings suggest that the levels of pathophysiologically
important biomarkers in SF of patients with OA and RA differ according
to the mechanisms that drive each disease. Thus, Il-1, Il-11, LIF and
OP-1 appear to be signiﬁcant for OA; while Il-6, Il-8, and OP-1 may have
signiﬁcance for RA. As previously observed in cartilage, a strong negative
correlation between the levels of OP-1 and Il-6 family of chemokines was
seen. Larger studies are necessary to develop a biomarker algorithm that
would be of diagnostic/prognostic use.
96 VASCULAR ABNORMALITIES PLAY KEY ROLES IN
OSTEOARTHRITIS: IMPLICATIONS FOR DETECTION AND
TREATMENT
P.A. Cheras. Southern Cross University, Lismore, AUSTRALIA
Purpose: Osteoarthritis (OA) is a multifactorial disease, the causes of
which remain contentious. The studies presented were designed to seek
evidence of vascular abnormalities in OA. These ﬁndings led to the formu-
lation of a “Vascular Concept of OA Causation” that incorporates currently
known laboratory, clinical and epidemiological data. This concept has
signiﬁcant implications for our approach to OA detection and treatment
and has been used to develop a rudimentary approach to early OA
detection.
Methods: Histological studies: Femoral heads removed from 11 OA
patients at hip arthroplasty were examined histologically for evidence of
microvascular thrombosis and occlusive intravascular lipid. They were
compared with seven control femoral heads obtained at post mortem
from donors in whom OA was excluded.
Haematological studies: Global and speciﬁc markers of coagulability,
ﬁbrinolysis, inﬂammation, matrix degradation and bone turnover were
measured in peripheral blood from 44 patients with OA of the hip and
52 control subjects.
Use of combinations of “markers” to detect OA: A subset of 12 potential
haematological markers and clinical measures was reﬁned and applied
to 45 subjects with OA and 47 control subjects to determine if the number
of markers per subject could be used as a guide to discriminate between
OA and non-OA subjects.
Results: Histological studies conﬁrmed the presence of occlusive in-
travascular lipid and thrombosis in the vessels of the femoral head of
patients with OA. These changes were not observed in the control femoral
heads. The haematological studies and clinical data showed increased
procoagulant tendency in OA with signiﬁcantly increased blood pressure,
BMI, blood lipids, platelet aggregation, clotting factors, blood viscosity and
ﬁbrinopeptide A levels. There was hypoﬁbrinolysis as shown by prolonged
euglobulin clot lysis time and raised plasminogen activator inhibitor, alpha
2 antiplasmin and LP(a) levels. Mild inﬂammation was demonstrated with
increased levels of Il-1, TNF alpha and CRP. Leukocyte elastase degrades
collagen and elastic ﬁbres and it was elevated in OA. There were also
increased levels of markers of bone turnover including ALP, BGP and DPD
crosslinks. All parameters were statistically signiﬁcant. Seventy percent
of OA patients had four or more markers versus only 15% of controls and
there was generally a combination of both increased coagulation risk and
hypoﬁbrinolysis in the osteoarthritis subjects.
These ﬁndings led to the formulation of a “Vascular Concept of OA Causa-
tion” that links vascular insufﬁciency to the clinical and laboratory ﬁndings
in OA. Based on this we propose that anti-arthritic agents that act on
the actual disease processes ought to enhance the joint microcirculation
and in addition to being anti-inﬂammatory they should also have core
activities that include anti-coagulant, ﬁbrinolytic and lipolytic activities that
will promote haemostasis.
Conclusions: Mounting evidence supports a key role for impaired blood
ﬂow in the initiation and progression of OA. Recognising the important
role of vascular insufﬁciency in OA creates new insights that could
lead to the early detection of OA. By expanding our focus to include
vascular abnormalities together with inﬂammation, this new perspective
can lead to the development of novel therapeutic targets for OA and more
comprehensive approaches to treatment that have the potential to slow
or halt the disease process. This concept also provides a rationale for
some of the strengths and inadequacies of current pharmacological and
complementary anti-arthritic medicines.
97 IS SERUM TRANSFORMING GROWTH FACTOR-BETA (TGF-b)
A BIOMARKER OF RADIOGRAPHIC OSTEOARTHRITIS (rOA)
AT THE KNEE AND HIP?
A.E. Nelson1, F. Fang2, V.B. Kraus3, T. Stabler3, J.B. Renner1,
C.G. Helmick4, J.M. Jordan1. 1University of North Carolina School of
Medicine, Chapel Hill, NC, USA, 2StatWorks, Inc, RTP, NC, USA, 3Duke
University Medical Center, Durham, NC, USA, 4Centers for Disease
Control and Prevention, Atlanta, GA, USA
Purpose: We have observed that African Americans (AA) are more likely
to have osteophytes at the hip and knee compared to Whites. Elevated
TGF-b has been associated with osteophyte formation in the OA joint.
Therefore, the purpose of the current study was to assess the utility of
serum TGF-b as a biomarker of rOA in AAs and Whites, men and women,
with and without hip and knee rOA.
Methods: Baseline data from 330 participants (42% AA; 39% men) in the
Johnston County Osteoarthritis Project Biomarker Substudy were used in
the analysis. Natural logarithm transformation was used to produce near-
normal distributions for TGF-b (lnTGF-b) in analyses. Descriptive statistics
were calculated for demographic variables, knee and hip rOA (deﬁned as
K/L grade  2 at each joint), and lnTGF-b; differences were assessed
by two-sample t-tests. Generalized linear models were used to obtain
least squared means estimates for lnTGF-b and rOA presence, laterality
(none, unilateral, or bilateral), and severity (K/L grade 0, 1 = none, K/L
grade 2=mild, K/L grade 3, 4 =moderate/severe). Models were adjusted
for age, gender, race, and body mass index (BMI). Interactions by race
and gender were considered signiﬁcant at a p-value <0.1. Analyses were
performed using SAS version 9.1 (Cary, NC).
Results: The mean age of the sample was 60.5±9.4 years, with a
mean BMI of 30.3±6.9 kg/m2; 54% had knee rOA and 22% had hip rOA.
The mean for lnTGF-b was 2.82±0.34 ng/mL. Mean lnTGF-b was higher
among AA participants compared to Whites (p = 0.0085), and women
compared to men (p = 0.0006). There were no signiﬁcant associations
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between lnTGF-b levels and age or BMI, and no signiﬁcant interactions
by race or gender were identiﬁed. No signiﬁcant differences were seen
for mean serum lnTGF-b levels by rOA status at the knee or the hip
in unadjusted or adjusted analyses (Table). There was a trend toward
increasing mean lnTGF-b with increasing severity at the knee in the
unadjusted analyses (p = 0.080) that was attenuated after adjustment
(p = 0.188). There was no association between lnTGF-b levels and unilat-
eral compared to bilateral knee or hip rOA in either unadjusted or adjusted
analyses.
Table: Least squared means of lnTGF-b by rOA outcome
Outcome Unadjusted
Mean
95%CI p value Adjusted
Mean
95%CI p value
HOA absent 2.80 2.76−2.85 0.713 2.80 2.76−2.85 0.862
HOA present 2.82 2.74−2.90 2.81 2.73−2.89
KOA absent 2.79 2.74−2.85 0.185 2.80 2.74−2.85 0.352
KOA present 2.84 2.79−2.89 2.83 2.78−2.88
KOA severity:
No KOA 2.79 2.74−2.85 n/a 2.79 2.74−2.85 n/a
Mild KOA 2.83 2.77−2.88 0.417* 2.82 2.76−2.88 0.505*
Mod/severe KOA 2.90 2.80−3.00 0.080* 2.88 2.77−2.99 0.188*
*p for comparison to no OA.
Conclusions: Although serum TGF-b was increased in AA compared
to Whites and in women compared to men, there were no signiﬁcant
associations with presence, laterality, or severity of knee or hip rOA,
suggesting that serum TGF-b is unlikely to be useful as a stand-alone
biomarker in OA studies.
98 COLL2−1, COLL2−1NO2 AND MYELOPEROXIDASE SERUM
LEVELS IN EROSIVE AND NON EROSIVE OSTEOARTHRITIS
OF THE HANDS
R. Ramonda1, M. Deberg2, C. Campana1, M. Frigato1, A. Bosseloir2,
Y. Henrotin2, L. Punzi1. 1Rheumatology Unit, University of Padova,
Padova, ITALY , 2Bone and Cartilage Research Unit, University of Lie`ge,
Lie`ge, BELGIUM
Purpose: Erosive osteoarthritis of the hand (EHOA) is thought to be an
aggressive variant of hand OA characterised by prominent local inﬂamma-
tion and radiographic aspects of bone erosions in interphalangeal joints.
Although serum levels of ultrasensitive CRP were found to be higher in
patients with EHOA in comparison with those with non-EHOA, biomarkers
have not been investigated until now in these patients.
Aims: (1) To determine Coll2−1, Coll2−1NO2 and myeloperoxydase
(MPO) levels in serum of patients with EHOA and compare these levels
with those of non-EHOA; (2) To investigate relationships between these
biomarkers and disease indices of severity and activity in EHOA.
Methods: Coll2−1, Coll2−1NO2 and MPO were measured in 82 patients,
62 with EHOA (57F and 5M, median age 59.5, range 41−74 years) and
20 with non-EHOA (all F, median age 55, range 43−73 years), fulﬁlling
ACR criteria for hand OA. EHOA was deﬁned in the presence of at least
one central bone erosion in the interphalangeal joints. Patients were also
evaluated for disease duration, number of affected (swollen or deformed)
joints, number of clinically active (swollen and painful or tender) (NCAJ),
radiographic score (RS), and number of active joints at bone scintigraphy
(NSAJ).
Results: Serum levels of Coll2−1NO2 and MPO were higher in patients
with EHOA (0.48±0.63 nM and 231.9±119.8 ng/ml, respectively) than in
those with non-EHOA (0.23±1.13 nM, p 0.067), although a signiﬁcance
was only reached by MPO (160.15± ng/ml, p< 0.043). No difference
was observed between the two groups for serum levels of Coll2−1. No
correlations were observed between the substances considered and the
other indices of disease activity or severity.
Conclusions: This is the ﬁrst study demonstrating an increase of
some serum biomarkers in EOA. In this context the most interesting
biomarker is MPO, although a trend for an elevation was also observed
for Coll2−1NO2.
99 A SENSITIVE AGGRECANASE ASSAY FOR
IN-VITRO/CELLULAR ACTIVITIES AND FOR TESTING
BIOLOGICAL SAMPLES
P.S. Chockalingam, V. Ramanathan, K.E. Georgiadis, S. Glasson,
E.A. Morris. Wyeth Research, Cambridge, MA, USA
Purpose: The loss of cartilage matrix in osteoarthritis (OA) is character-
ized by increased loss of type II collagen and aggrecan by collagenases
and aggrecanases, respectively. Depletion of aggrecan is an early and an
important event in OA. We have observed ongoing aggrecanase activity
in late stage human osteoarthritic cartilage. Inhibition of aggrecanase
activity and upstream effectors may offer an attractive therapeutic target
for OA. Methods to detect and quantify aggrecanase activity for OA target
identiﬁcation/validation, screening of compounds, and to test activity
in biological/clinical samples is gaining great importance. A sensitive
aggrecanase ELISA has been developed to detect pM levels of both in-
vitro as well as cellular aggrecanase activities.
Methods: Either of two custom-made, C-terminal biotinylated, ‘aggre-
canase cleavage site’ (G373-374A) containing aggrecan interglobular do-
main (IGD) peptides (51/58mer) was used as the substrate. Samples
with or without inhibitors were added to the peptide-coated plate and
incubated. Cleaved aggrecan was detected by HRP-BC3 (anti-ARGS),
aggrecanase activity quantiﬁed, and IC50 determined. The assay was
also used to measure aggrecanase activity in synovial ﬂuid samples of
rats where the animals were oral dosed with drug and knee synovial ﬂuid
samples collected after intra-articular injection of aggrecanase. For the
cell-based assay format, primary bovine chodrocytes were cultured onto
peptide-coated plates followed by Il-1a induction with or without inhibitors.
Cellular activity was measured both in cell extracts and in conditioned
media to study the efﬁcacy of inhibitors.
Results: The in-vitro/cell-based 96-well format aggrecanase activity as-
say was found to be very selective and sensitive (detection range of
0.01−1 nM aggrecanase). IC50 values of aggrecanase inhibitors tested
in the ELISA were comparable to the FRET IC50s. The ELISA used
70−75 fold less enzyme than the FRET assay. IC50 determination was
not limited at low nM ranges in the ELISA as compared to the FRET
that could not determine IC50s below 30nM. The assay detected intra-
articularly injected aggrecanase activity in the diluted knee synovial ﬂuid
samples of rats dosed with drug and determined the inhibitory level
reﬂecting in-vivo drug efﬁcacy. In the cell-based assay format, primary
bovine chondrocytes produced aggrecanase activity upon Il-1 induction.
This activity was detected in the assay enabling a higher-throughput cell
based screening of aggrecanase inhibitors as compared to bovine explant
cultures.
Conclusions: The sensitive in-vitro/cellular aggrecanase activity ELISA
uses a longer IGD peptide of aggrecan that better represents the bio-
logical substrate as compared to the FRET peptide (10mer). This assay
is more sensitive as compared to the FRET and could determine IC50s
at low nM levels. The cell-based format of the assay would be useful for
chondrocyte-based secondary screening of aggrecanase inhibitors at a
higher throughput. This can also be extended to other purposes including
identiﬁcation/validation of OA targets (example: aggrecanase activity in
response to knockdown/over expression of potential OA targets in primary
human chondrocytes). Thus, the assay has the added advantage of
detecting cellular activity that would not be possible with the existing
commercial aggrecanase activity assays. The assay has been used
to monitor in-vivo drug efﬁcacy in animal models. The application of
this assay to detect activity in human synovial ﬂuids is currently being
evaluated.
100 PREDICTING RADIOGRAPHIC JOINT SPACE NARROWING
(JSN) USING BIOMARKERS FOR OSTEOARTHRITIS (OA)
CLINICAL TRIALS
O. Nemirovskiy1, R. Buck2, T. Sunyer1, M. Abrams1, P. Aggarwal1,
D. Duﬁeld1, M. Radabaugh1, W. Mathews1, M-P. Hellio Le Graverand2.
1Pﬁzer, Inc., St. Louis, MO, USA, 2Pﬁzer, Inc., Groton, CT, USA
Purpose: To identify biochemical markers that predict OA progression.
Such prognostic biomarkers could provide valuable inclusion criteria for
clinical efﬁcacy trials to decrease the variability within patient populations
as well as to decrease the time required to detect a signiﬁcant change
in the outcome in response to treatment. We studied the relationship
between several biochemical markers and radiographic joint space nar-
rowing (JSN) (i.e., change in joint space width (JSW)) in OA patients over
2 years.
Methods: Urine, serum, and plasma samples were collected at 5 visits:
0, 3, 6, 12, and 24 months from healthy (n = 85) and OA human subjects
with symptomatic knee OA (n = 75). The diagnosis of OA was based on
a combination of pain or stiffness on most days of a month during the
past year and the presence of radiographic OA as deﬁned by Kellgren
and Lawrence grades (KLG) 0, 1, 2 and 3. Knee radiographs were
taken using the Lyon-Schuss protocol at 0 (baseline), 12, and 24 month.
Samples were analyzed for the levels of cartilage, bone, and synovium
matrix degradation and synthesis markers as well as for markers of
